SL
PTGX icon

Salomon & Ludwin’s Protagonist Therapeutics PTGX Stock Holding History

Salomon & Ludwin’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.5K Hold
595
– – 0.01% 364
2026
Q1 		$61.7K Buy
595
+159
+36% +$14.1K 0.01% 397
2025
Q4 		$36.7K Sell
436
-6
-1% -$491 ﹤0.01% 511
2025
Q3 		$28.7K Buy
+442
New +$25.1K ﹤0.01% 607

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Salomon & Ludwin's PTGX Position: Q2 2026 in Review

Salomon & Ludwin held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 595 shares worth $74.5K. The position accounts for 0.01% of the portfolio, ranked #364.

Salomon & Ludwin first reported a position in PTGX in Q3 2025 and has held it in 4 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Salomon & Ludwin held 595 shares of Protagonist Therapeutics worth $74.5K as of Q2 2026.
  • Salomon & Ludwin left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up 0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #364 holding.
  • Salomon & Ludwin first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.